Biotechnology
Technology
Health
Kadmon
$2.219876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.08 (-3.49%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Kadmon and other stocks, options, ETFs, and crypto commission-free!
About
Kadmon Holdings, Inc., also called Kadmon, is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Read More Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.
Employees
116
Headquarters
New York, New York
Founded
2010
Market Cap
290.62M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
828.12K
High Today
$2.27
Low Today
$2.20
Open Price
$2.26
Volume
52.85K
52 Week High
$4.39
52 Week Low
$1.88
Collections
Biotechnology
Technology
Health
Biopharmaceutical
Pharmaceutical
2016 IPO
US
North America
News
Yahoo FinanceMay 9
Kadmon Provides Business Update and Reports First Quarter 2019 Financial Results
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Kadmon Holdings, Inc. (KDMN) today provided a business update and reported financial and operational results for the first quarter of 2019. ''The advancement of KD025 for the treatment of cGVHD continues to be Kadmon's key priority. We recently held a Type B Breakthrough Therapy meeting with the FDA and remain aligned with the Agency on our registration study design and the broader data package to support a potential New Drug Application,'' said Harlan W. Waksal, M...
Price Paid on Robinhood
34% Lower
Right Now
52 Week Low
$1.88
Average Price Paid
$3.34
52 Week High
$4.39
Earnings
-$0.42
-$0.27
-$0.13
$0.02
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.16 per share
Actual
$0.02 per share